FAK can also have an impact in the tumor microenvironment of AML; indeed, the previously cited VS-4718 FAK inhibitor (1.25–2.5 μM) and FAK gene silencing were able to induce a decrease in the adhesion and migration of OCI-AML3 cells to bone-marrow derived MSCs, thus suggesting how FAK inhibition can affect leukemia cells-stroma interaction (Figure 3). The gene discussed is PTK2; the disease is leukemia.